Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-R rollover study of opnurasib in participants benefiting from prior Novartis studies
2025-523537-26-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of opnurasib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by Novartis. Primary endpoint: Treatment exposure. Planned start Jul 2026; status: authorised.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-523537-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523537-26-00.